$61.98
Market Capitalization | 5.8B |
Book Value | $27.53 |
Earnings Per Share (EPS) | 0.39 |
PE Ratio | 158.92 |
PEG Ratio | 1.58 |
Wall Street Target Price | 61.43 |
Profit Margin | 0.77% |
Operating Margin TTM | 6.76% |
Return On Assets TTM | 2.3% |
Return On Equity TTM | 0.8% |
Revenue TTM | 2.6B |
Revenue Per Share TTM | 28.38 |
Quarterly Revenue Growth YOY | -0.8% |
Gross Profit TTM | 1.0B |
EBITDA | 411.1M |
Diluted Eps TTM | 0.39 |
Quarterly Earnings Growth YOY | 0.17 |
EPS Estimate Current Year | 2.27 |
EPS Estimate Next Year | 2.79 |
EPS Estimate Current Quarter | 0.55 |
EPS Estimate Next Quarter | 0.58 |
What analysts predicted
Downside of 0.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.5B | ↓ 2.65% |
Net Income | -244.7M | ↓ 677.12% |
Net Profit Margin | -7.02% | ↓ 8.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.3B | ↓ 5.08% |
Net Income | -346.0M | ↑ 41.4% |
Net Profit Margin | -10.46% | ↓ 3.44% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↓ 19.14% |
Net Income | -55.9M | ↓ 83.84% |
Net Profit Margin | -2.09% | ↑ 8.37% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.6B | ↓ 1.07% |
Net Income | -26.8M | ↓ 52.06% |
Net Profit Margin | -1.01% | ↑ 1.08% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↑ 2.18% |
Net Income | 56.0M | ↓ 308.96% |
Net Profit Margin | 2.07% | ↑ 3.08% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↓ 1.68% |
Net Income | -21.4M | ↓ 138.21% |
Net Profit Margin | -0.8% | ↓ 2.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 684.3M | ↑ 2.07% |
Net Income | 11.2M | ↓ 64.78% |
Net Profit Margin | 1.64% | ↓ 3.1% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 669.5M | ↓ 2.16% |
Net Income | -49.5M | ↓ 541.96% |
Net Profit Margin | -7.39% | ↓ 9.03% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 653.5M | ↓ 2.39% |
Net Income | 2.0M | ↓ 104.04% |
Net Profit Margin | 0.31% | ↑ 7.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 652.0M | ↓ 0.23% |
Net Income | 14.9M | ↑ 645.0% |
Net Profit Margin | 2.29% | ↑ 1.98% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 664.9M | ↑ 1.98% |
Net Income | 13.1M | ↓ 12.08% |
Net Profit Margin | 1.97% | ↓ 0.32% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 661.6M | ↓ 0.5% |
Net Income | 6.0M | ↓ 54.2% |
Net Profit Margin | 0.91% | ↓ 1.06% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↓ 7.62% |
Total Liabilities | 3.9B | ↓ 5.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 6.4B | ↓ 0.29% |
Total Liabilities | 4.1B | ↑ 6.32% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 5.6B | ↓ 13.28% |
Total Liabilities | 3.1B | ↓ 23.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 5.5B | ↓ 1.95% |
Total Liabilities | 3.1B | ↓ 2.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 5.3B | ↓ 2.54% |
Total Liabilities | 2.9B | ↓ 5.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 5.4B | ↑ 0.35% |
Total Liabilities | 2.8B | ↓ 2.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.3B | ↓ 0.04% |
Total Liabilities | 2.9B | ↓ 0.81% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.2B | ↓ 2.23% |
Total Liabilities | 2.7B | ↓ 5.4% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.2B | ↑ 0.63% |
Total Liabilities | 2.8B | ↑ 1.45% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.4B | ↑ 2.03% |
Total Liabilities | 2.8B | ↑ 2.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 5.4B | ↑ 1.55% |
Total Liabilities | 2.9B | ↑ 2.93% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 5.5B | ↑ 0.76% |
Total Liabilities | 2.9B | ↑ 1.09% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 165.7M | ↓ 67.42% |
Investing Cash Flow | -147.5M | ↓ 23.58% |
Financing Cash Flow | -25.7M | ↓ 92.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 248.0M | ↑ 49.67% |
Investing Cash Flow | -104.0M | ↓ 29.49% |
Financing Cash Flow | -141.6M | ↑ 450.97% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 530.2M | ↑ 113.79% |
Investing Cash Flow | 381.4M | ↓ 466.73% |
Financing Cash Flow | -892.5M | ↑ 530.3% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 303.1M | ↓ 42.83% |
Investing Cash Flow | -90.1M | ↓ 123.62% |
Financing Cash Flow | -207.9M | ↓ 76.71% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 200.2M | ↓ 33.95% |
Investing Cash Flow | -84.6M | ↓ 6.1% |
Financing Cash Flow | -110.7M | ↓ 46.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 49.5M | ↓ 68.49% |
Investing Cash Flow | -34.5M | ↓ 282.54% |
Financing Cash Flow | -11.6M | ↓ 93.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 105.4M | ↑ 112.93% |
Investing Cash Flow | 60.9M | ↓ 276.52% |
Financing Cash Flow | -196.3M | ↑ 1592.24% |
Sell
Neutral
Buy
Stericycle, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Vanguard Group Inc
BlackRock Inc
Capital Research Global Investors
Clarkston Capital Partners, LLC
Black Creek Investment Management Inc
Impax Asset Management Group PLC
stericycle is a global services company. we provide highly specialized solutions serving healthcare organizations and commercial businesses of every size and shape. throughout the last 25 years, we have grown from a small start-up in medical waste management into a leader across a range of increasingly complex and highly regulated arenas, such as: • brand protection solutions • environmental & sustainable solutions • patient & customer communication solutions • regulated waste management & compliance solutions from the start we have challenged the status quo of what a business solution can be. by identifying unmet needs, we have redefined and transformed multiple industries from a narrowly defined service category to a robust suite of solutions that customers need and want. our success with this strategy has landed stericycle among the fortune 1000 list and forbes 25 most innovative companies. a publicly-traded company with $2.5 billion in 2014 revenue, our core purpose is to
Organization | Stericycle, Inc. |
Employees | 13095 |
CEO | Ms. Cindy J. Miller |
Industry | Health Services |